These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 4826499)

  • 1. Enhancement of antitumor effectiveness of ICRF-159 (NSC-129943) against early L1210 leukemia by combination with cis-diamminedichloroplatinum (NSC-119875) or daunomycin (NSC-82151).
    Woodman RJ
    Cancer Chemother Rep 2; 1974 Mar; 4(1):45-52. PubMed ID: 4826499
    [No Abstract]   [Full Text] [Related]  

  • 2. Enhancement of the effectiveness of daunorubicin (NSC-82151) or adriamycin (NSC-123127) against early mouse L1210 leukemia with ICRF-159 (NSC-129943).
    Woodman RJ; Cysyk RL; Kline I; Gang M; Venditti JM
    Cancer Chemother Rep; 1975; 59(4):689-95. PubMed ID: 1175163
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Studies in mice treated with ICRF-159 combined with daunorubicin or doxorubicin.
    Giuliani F; Casazza AM; Di Marco A; Savi G
    Cancer Treat Rep; 1981; 65(3-4):267-76. PubMed ID: 6263470
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synergistic effect of ricin in combination with daunorubicin, cis-dichlorodiammineplatinum(II) and vincristine in systemic L1210 leukemia.
    Fodstad O; Pihl A
    Cancer Res; 1982 Jun; 42(6):2152-8. PubMed ID: 7200398
    [No Abstract]   [Full Text] [Related]  

  • 5. Letter: ICRF 159.
    Bellet RE; Mastrangelo MJ; Dixon LM
    Lancet; 1974 May; 1(7863):926. PubMed ID: 4133440
    [No Abstract]   [Full Text] [Related]  

  • 6. Activity of anthracyclines against an adriamycin (NSC-123127)-resistant subline of P388 leukemia with special emphasis on cinerubin A (NSC-18334).
    Johnson RK; Ovejera AA; Goldin A
    Cancer Treat Rep; 1976 Jan; 60(1):99-102. PubMed ID: 826316
    [No Abstract]   [Full Text] [Related]  

  • 7. Potentially useful combinations of chemotherapy detected in mouse tumor systems.
    Kline I
    Cancer Chemother Rep 2; 1974 Mar; 4(1):33-43. PubMed ID: 4133187
    [No Abstract]   [Full Text] [Related]  

  • 8. Antitumor effect of 1-beta-D-arabinofuranosylcytosine 5'-adamantoate (NSC 117614) in L1210 leukemic mice.
    Neil GL; Wiley PF; Manak RC; Moxley TE
    Cancer Res; 1970 Apr; 30(4):1047-54. PubMed ID: 5504347
    [No Abstract]   [Full Text] [Related]  

  • 9. Schedule-dependent synergism for the combination of 1-beta-D-arabinofuranosylcytosine and daunorubicin.
    Edelstein M; Vietti T; Valeriote F
    Cancer Res; 1974 Feb; 34(2):293-7. PubMed ID: 4810905
    [No Abstract]   [Full Text] [Related]  

  • 10. Antitumor activity of a water-insoluble compound entrapped in liposomes on L1210 leukemia in mice.
    Brassinne C; Atassi G; Frühling J; Penasse W; Coune A; Hildebrand J; Ruysschaert JM; Laduron C
    J Natl Cancer Inst; 1983 Jun; 70(6):1081-6. PubMed ID: 6574278
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Antitumor activity of adriamycin].
    Kitaura K; Watanabe Y; Ishihara Y; Takahira H
    Jpn J Antibiot; 1972 Apr; 25(2):65-71. PubMed ID: 4341940
    [No Abstract]   [Full Text] [Related]  

  • 12. Daunomycin- and adriamycin-N-(2-hydroxypropyl)methacrylamide copolymer conjugates; toxicity reduction by improved drug-delivery.
    Seymour LW; Duncan R; Kopecková P; Kopecek J
    Cancer Treat Rev; 1987 Dec; 14(3-4):319-27. PubMed ID: 3326668
    [No Abstract]   [Full Text] [Related]  

  • 13. Effects of 4,4'-diacetyl-diphenyl-urea-bis(guanylhydrazone) on leukemia L1210.
    Mihich E; Mulhern AI
    Cancer Res; 1968 Feb; 28(2):354-62. PubMed ID: 5641525
    [No Abstract]   [Full Text] [Related]  

  • 14. [Possibility of utilizing lymphatic leukemia L1210 as a first screening model in the primary selection of new antitumor antibiotics].
    Shorin VA; Bazhanov VS
    Antibiotiki; 1974 Aug; 19(8):679-84. PubMed ID: 4455117
    [No Abstract]   [Full Text] [Related]  

  • 15. Influence of antileukemic (L1210) treatment schedule on disposition of (minus)-emetine hydrochloride (NSC 33669) in normal and leukemic mice.
    Auletta AE; Gery AM; Mead JA
    Cancer Res; 1974 Jul; 34(7):1581-5. PubMed ID: 4833911
    [No Abstract]   [Full Text] [Related]  

  • 16. Activity of a novel anthracenyl bishydrazone, 9,10-anthracenedicarboxyaldehyde Bis[(4,5-dihydro-1H-imidazol-2-yl)hydrazone] dihydrochloride, against experimental tumors in mice.
    Citarella RV; Wallace RE; Murdock KC; Angier RB; Durr FE; Forbes M
    Cancer Res; 1982 Feb; 42(2):440-4. PubMed ID: 7055799
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Letter: Daunomycin (NSC-82151) and adriamycin (NSC-123127): a hypothesis concerning antitumor activity and cardiotoxicity.
    Adamson RH
    Cancer Chemother Rep; 1974; 58(3):293-4. PubMed ID: 4841712
    [No Abstract]   [Full Text] [Related]  

  • 18. Comparison of the antileukemic effect in mice of adriamycin (NSC-123127) with daunomycin (NSC-82151).
    Sandberg JS; Howsden FL; DiMarco A; Goldin A
    Cancer Chemother Rep; 1970 Feb; 54(1):1-7. PubMed ID: 5527012
    [No Abstract]   [Full Text] [Related]  

  • 19. DNA--anthracycline complexes. I. Toxicity in mice and chemotherapeutic activity against L1210 leukemia of daunorubicin--DNA and adriamycin--DNA.
    Deprez-de Campeneere D; Trouet A
    Eur J Cancer (1965); 1980 Aug; 16(8):981-6. PubMed ID: 7439227
    [No Abstract]   [Full Text] [Related]  

  • 20. Preclinical toxicology studies with ICRF-159 (NSC-129943)--a new antineoplastic drug.
    Gralla EJ; Coleman GL; Jonas AM
    Cancer Chemother Rep 3; 1974 Sep; 5(1):1-7. PubMed ID: 4213305
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.